Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for lymphocytic hypereosinophilic syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for lymphocytic hypereosinophilic syndrome.
21 publications have been identified in PubMed for lymphocytic hypereosinophilic syndrome. Research spans Review / Meta-Analysis (24%), Diagnostic / Biomarker (14%), and Case Report / Case Series (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 5 | 24% |
Data assembled from 3 of 12 sources · Last updated Nov 4, 2026, 2:15 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Testing and diagnosis research
3 |
14% |
Patient case studies | 3 | 14% |
Laboratory research | 3 | 14% |
Disease patterns and progression | 3 | 14% |
New treatment approaches | 2 | 10% |
Other research | 1 | 5% |
Clinical study results | 1 | 5% |
Węgierek-Ciura K (2026). [PMID: 41846923](https://pubmed.ncbi.nlm.nih.gov/41846923/). *Front Immunol*. [Gene Therapy / Novel Therapeutics]
Hanna C (2026). [PMID: 41793580](https://pubmed.ncbi.nlm.nih.gov/41793580/). *Curr Hematol Malig Rep*. [Review / Meta-Analysis]
Catherine J (2025). [PMID: 39788434](https://pubmed.ncbi.nlm.nih.gov/39788434/). *J Allergy Clin Immunol*. [Clinical Trial Publication]
Le Rochais M (2025). [PMID: 40398138](https://pubmed.ncbi.nlm.nih.gov/40398138/). *Immunobiology*. [Diagnostic / Biomarker]
Tabata R (2025). [PMID: 39278207](https://pubmed.ncbi.nlm.nih.gov/39278207/). *Int Arch Allergy Immunol*. [Other]
Trabanelli S (2025). [PMID: 40721674](https://pubmed.ncbi.nlm.nih.gov/40721674/). *Nat Neurosci*. [Basic Science / Preclinical]
Tefft K (2025). [PMID: 41178717](https://pubmed.ncbi.nlm.nih.gov/41178717/). *J Clin Invest*. [Basic Science / Preclinical]
Liu Z (2025). [PMID: 41362199](https://pubmed.ncbi.nlm.nih.gov/41362199/). *Clin Lab*. [Case Report / Case Series]
Stammler R (2025). [PMID: 40992688](https://pubmed.ncbi.nlm.nih.gov/40992688/). *J Allergy Clin Immunol Pract*. [Epidemiology / Natural History]
Wang XQ (2025). [PMID: 40161869](https://pubmed.ncbi.nlm.nih.gov/40161869/). *EJHaem*. [Case Report / Case Series]
AI-curated news mentioning lymphocytic hypereosinophilic syndrome
Updated Oct 1, 2026
A multicenter real-world study demonstrates sustained low disease activity in patients with FIP1L1::PDGFRA-negative hypereosinophilic syndrome treated with mepolizumab. This research highlights the potential long-term benefits of mepolizumab in managing this rare condition.
A recent study published in PubMed reveals the incidence and prevalence of hypereosinophilic syndrome in the United States, utilizing a retrospective claims database. This research provides valuable insights into the epidemiology of this rare disease.
A multicenter case series highlights the use of ruxolitinib in patients with life-threatening corticosteroid-refractory hypereosinophilic syndrome. This study contributes to the understanding of treatment options for this rare condition.